Salem Radio Network News Tuesday, November 17, 2026

Health

AI drug developer Isomorphic raises $5 billion in Series C round

Carbonatix Pre-Player Loader

Audio By Carbonatix

Nov 17 (Reuters) – Isomorphic Labs said on Tuesday it has raised $5 billion in a Series C funding round co-led by Greenoaks and Sequoia Capital, as the Alphabet-backed AI drug discovery company works to move its first drug candidates into clinical trials.

The company, which was spun out of Google DeepMind in 2021, declined to share its valuation. The funding comes about six months after it raised $2.1 billion in a Series B round led by Thrive Capital.

Here are more details:

• Andreessen Horowitz and other new investors joined the round, while Alphabet made a significant investment and other existing backers, including Thrive, MGX and GV, also participated

• “This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients,” Isomorphic founder and CEO Demis Hassabis said

• The company is developing its IsoDDE drug design engine, which uses AI to design new drugs, predict their properties and refine them before scientists decide on the candidates to make and test

• Isomorphic said it has seen positive pre-clinical results in internal oncology and immunology programs and with partners, “setting the stage for clinical entry”

• The company lists Novartis, Eli Lilly and Johnson & Johnson as its partners, according to its website

(Reporting by Prathik Jayaprakash in Bengaluru; Editing by Leroy Leo)

Previous
Next
The Media Line News
X CLOSE